|Bid||112.00 x 1100|
|Ask||123.20 x 800|
|Day's Range||112.06 - 116.04|
|52 Week Range||98.56 - 278.62|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||3.48|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 2,500 shares of LGND on 05/14/2019 at an average price of $113.5 a share.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Ligand Pharmaceuticals Inc NASDAQ NMS:LGNDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is extremely high for LGND with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting LGND. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding LGND are favorable, with net inflows of $3.59 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In an continued effort to fund the company without hurting its already-down stock value, Novan has announced another $12 million deal to forward its lead drug trials.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: ...
Ligand (LGND) delivered earnings and revenue surprises of -95.92% and 13.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had profit of $31.32 per share. Earnings, adjusted for one-time gains and costs, came to $1.16 per share. The drugmaker posted revenue of $43.5 million in the period. ...
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are always looking for growth in small-cap stocks like Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), with a market cap of US$2.6b. However, an important fact which most ignore is: how financially healthy is the business...
CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 2,500 shares of LGND on 03/13/2019 at an average price of $114.29 a share.